PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)

Trial Profile

PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2016 Status changed from recruiting to discontinued due to Poor enrolment.
    • 22 Jul 2014 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.
    • 16 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top